China Resources Double-Crane Pharmaceutical Co Ltd

China Resources Double-Crane announced that its wholly owned subsidiary China Resources Saike has received the Drug Registration Certificate for Ezetimibe and Atorvastatin Calcium Tablets (I) and (II) issued by the National Medical Products Administration. The two specifications contain 10 mg of ezetimibe with 10 mg and 20 mg of atorvastatin calcium per tablet respectively, are registered as Category 4 chemical drugs, and are deemed to have passed the consistency evaluation. The drug is indicated for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia. The announcement shows that China Resources Saike submitted the marketing application in May 2025, with cumulative research and development investment of approximately 20.36 million yuan.

China Resources Double-Crane announced that its Lomustine Capsules, filed as the domestic agent, have received a drug registration certificate from the National Medical Products Administration. The specification is 40 mg, and the registration classification is chemical drug category 5.1. It is indicated for children and adult patients with primary malignant brain tumors, and enjoys a six-year data protection period. The product was introduced by the company from Latina Pharma S.P.A in early 2024, with a marketing authorization application submitted in January 2024. Cumulative research and development investment is approximately 2.23 million yuan.

China Resources Double-Crane announced that its wholly-owned subsidiary, Shanghai Changzheng Fumin Jinshan Pharmaceutical, has received a drug registration certificate from the National Medical Products Administration for Sodium Lactate Ringer's Irrigation Solution. The product has a specification of 3000 milliliters and is registered as a Category 3 chemical drug, deemed to have passed consistency evaluation. It is indicated for general irrigation where sterile electrolyte solutions are permitted. The originator product was developed by B. Braun of the United States, approved for marketing in the US in 1986, and has not been approved in China. Currently, the domestic manufacturers with approved marketing authorization are Shijiazhuang No. 4 Pharmaceutical and Shanghai Changzheng Fumin, both deemed to have passed consistency evaluation.

China Resources Double-Crane's controlled subsidiary Zhongshuai Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for acetazolamide extended-release capsules. The drug has a strength of 0.5 grams, is registered as a Category 3 chemical drug, and is deemed to have passed the consistency evaluation. The announcement states that the drug is used to prevent or improve symptoms of acute mountain sickness.

China Resources Double-Crane announced that its wholly-owned subsidiary Double-Crane Limin has completed the registration and public disclosure of the Phase III clinical trial for pregabalin extended-release tablets. The trial evaluated the efficacy and safety of the drug in treating postherpetic neuralgia, with conclusions showing clear efficacy, rapid onset, stable long-term efficacy, and good safety. The drug is a gamma-aminobutyric acid receptor blocker, and currently only Jiangsu Hengrui Medicine has been approved for marketing in China. As of the announcement date, cumulative R&D investment reached 27.3547 million yuan.

This evening, nearly 100 companies listed on the Shanghai Stock Exchange released a flurry of positive signals, spanning share buybacks and stake increases, improving business performance, proposed selections in centralized drug procurement, and interim dividend returns. On the buyback and stake increase front, two new buyback plans were added by Bethel Automotive Safety Systems and Shandong Hi-Speed, with a combined proposed buyback cap of 400 million yuan. Soochow Securities disclosed a controlling shareholder's stake increase plan, with a proposed increase amount not exceeding 200 million yuan, while another 76 companies simultaneously disclosed progress updates on buybacks and stake increases. At the operational level, results of the 12th round of national centralized drug procurement were gradually announced, with multiple Shanghai-listed pharmaceutical companies including Harbin Pharmaceutical Group, Zhejiang Huahai Pharmaceutical, China Resources Double-Crane Pharmaceutical, North China Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, Aurisco Pharmaceutical, and Jianfeng Group declaring that their products have been proposed for selection. In terms of investor returns, four companies—WuXi AppTec, Zhejiang Jiuzhou Pharmaceutical, Kingfa Sci. & Tech., and Jasan Group—unveiled interim dividend plans on the same day. Among them, WuXi AppTec plans to distribute a cash dividend of 5.1 yuan per 10 shares, with the total interim dividend expected to exceed 1.5 billion yuan. Additionally, the controlling shareholder of Lujiazui voluntarily committed not to transfer or reduce its holdings in any way within the next 12 months, coinciding with the unlocking of restricted shares from the company's private placement.

Glufosinate-ammonium leader Lier Chemical opened at its daily limit up on July 30, briefly broke the board during the session before sealing back at 16.18 yuan, with over 200,000 lots in unfilled buy orders and a latest market cap of 12.9 billion yuan. In related news, China Resources Double-Crane plans to acquire a 23.5% stake in Lier Chemical via cash payment, at a transfer price of 30.07 yuan per share, for a total consideration of 5.656 billion yuan. Upon completion of the transaction, Lier Chemical's controlling shareholder will change to China Resources Double-Crane, and its actual controller will become China Resources Company Limited. The deal is expected to constitute a major asset restructuring.

China Resources Double-Crane announced plans to acquire a combined 23.50% stake in Lier Chemical through a cash payment, with a total consideration of 5.656 billion yuan, and will gain control of Lier Chemical upon completion. Specifically, it will purchase a 20% stake from Sichuan Jiuyuan Investment Holding Group and a 3.50% stake from Sichuan Huacai Technology, at a transfer price of 30.07 yuan per share, totaling 188 million shares. Lier Chemical is the largest domestic producer of chloropyridine pesticide technicals and formulations, and also a large-scale producer of glufosinate and refined glufosinate technicals. China Resources Double-Crane has been building its presence in the biomanufacturing sector since 2022 and has stockpiled multiple synthetic biology pesticide products but lacks an industrialization platform. This acquisition can rapidly achieve the industrialization of its technology and products, building a second growth curve in synthetic biology.

Based on the equity registration date, a total of 20 listed companies will implement their dividend plans today. Among them, 11 companies have a cash dividend of 1 yuan or more per 10 shares. Huayu Automotive is the most generous, distributing 10.00 yuan per 10 shares, followed by Youyou Green Energy and China Resources Double-Crane, with cash dividends of 8.00 yuan and 3.79 yuan per 10 shares respectively. In terms of share transfers, Zhixin Precision and Youyou Green Energy both transfer 4.00 shares per 10 shares, the highest transfer ratio. Looking at share price performance over the past five days, Huaneng Mengdian leads with a cumulative gain of 7.02 percent, while Jinhai High-Tech and Huayu Automotive rose 3.88 percent and 2.72 percent respectively.

China Resources Double-Crane, an indirect non-wholly-owned subsidiary of China Resources Pharmaceutical, has participated in the acquisition of 188 million shares of Lier Chemical, representing approximately 23.50% of Lier Chemical's equity. China Resources Double-Crane received notice from the seller confirming that it is the top-ranked intended transferee in the above-mentioned public solicitation transfer. Lier Chemical is mainly engaged in the research, development, production and sales of high-efficiency, low-toxicity, low-residue and safe pesticide active ingredients and pesticide formulations.

China Resources Double-Crane announced that its wholly owned subsidiary, Shanxi Jinxin Double-Crane Pharmaceutical, has received the Drug Registration Certificate for Progesterone Soft Capsules from the National Medical Products Administration. The drug is indicated for the treatment of functional disorders caused by progesterone deficiency and is deemed to have passed the consistency evaluation. As of the announcement date, the company has invested a cumulative 17.2675 million yuan in research and development.